World Hypopara Awareness Day is June 1!
Join us in raising awareness for people living with hypoparathyroidism and share this link.

Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA

January 24, 2023

Download a PDF: EN or FR

Advancing peptides for the treatment of rare endocrine and related diseases

We are a clinical stage, global company, building on our team’s established expertise to transform the lives of patients living with rare endocrine and related diseases.

PROGRAMS

Eneboparatide

Our lead clinical candidate is a potentially clinically superior therapeutic peptide in development for hypoparathyroidism.

Eneboparatide (red) bound to the PTH1 receptor. Adapted from Zhao et al. Science 364:138, 2019.
Image generated with the PyMOL Molecular Graphics System, Version 2.3.2 Schrödinger, LLC.

AZP-3813

AZP-3813 is a highly potent, peptide growth hormone (GH) receptor antagonist in development for acromegaly.

HUMAN GROWTH HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR: CRYSTAL STRUCTURE OF THE COMPLEX. de Vos, A.M., Ultsch, M., Kossiakoff, A.A. (1992) Science 255: 306-312. Image created with Mol* (D. Sehnal, A.S. Rose, J. Kovca, S.K. Burley, S. Velankar (2018) Mol*: Towards a common library and tools for web molecular graphics MolVA/EuroVis Proceedings. doi:10.2312/molva.20181103). RCSB Protein Data Bank, PDB ID: 3HHR.

LEADERSHIP

Our management team has the collective and proven expertise necessary to advance its portfolio of innovative therapies in the clinic.

Press Releases & Recent News

Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA

January 24, 2023

Download a PDF copy of this press release: EN FR Amolyt to advance pre-clinical development of anti-PTHR1 monoclonal antibodies as …

Written by

Dan Hennings

Download a PDF: EN or FR

Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group

January 6, 2023

Download a PDF copy of this press release: EN FR Funds will be used to complete phase 3 clinical development …

Written by

Dan Hennings

Download a PDF: EN or FR

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
elementor	never	This cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_devsite	2 years	This cookie is installed by Google Analytics.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.

Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA

Advancing peptides for the treatment of rare endocrine and related diseases

We are a clinical stage, global company, building on our team’s established expertise to transform the lives of patients living with rare endocrine and related diseases.

PROGRAMS

Eneboparatide

Our lead clinical candidate is a potentially clinically superior therapeutic peptide in development for hypoparathyroidism.

AZP-3813

AZP-3813 is a highly potent, peptide growth hormone (GH) receptor antagonist in development for acromegaly.

LEADERSHIP

Our management team has the collective and proven expertise necessary to advance its portfolio of innovative therapies in the clinic.

Press Releases & Recent News

Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA

Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group

Join Our Team

We are always looking for talented and driven individuals to join our diverse and collaborative team to help us achieve our mission.

Contact Us

We welcome open and continuous dialogue with all interested parties, including patients, healthcare providers, potential partners and investors.